# A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

> **NCT03757000** · PHASE1 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- B-cell Lymphoma Recurrent
- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT03757000
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-25
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2018-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757000, "A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03757000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*